ClinicalTrials.gg
Active, not recruitingNCT02286154TREATUpdated Jul 17, 2025

Therapeutic Response Evaluation and Adherence Trial (TREAT)

An interventional study of Hydroxyurea in Anemia, Sickle Cell, sponsored by Children's Hospital Medical Center, Cincinnati. Active, not recruiting at 1 site in United States. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
6 Months to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies testing hydroxyurea in Anemia, Sickle Cell — 8 open to participants now, 14 under way, 1 of them phase 3. Hydroxyurea · Anemia, Sickle Cell.

Planned enrollment
15th of 57
150 · median 50
Started
2014
with 7 others
No phase
7 of 59
1 open now
Primary completion
2026-12
later than 6 of 13 live
Registered
27th of 59
by date
Lead sponsor
9 of 59
Children's Hospital Medical Center, Cincinnati

Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, this one is the 15th largest by planned enrollment of the 57 interventional ones that give a count, is one of 8 that started in 2014, is one of 7 with no phase, reaches primary completion later than 6 of the 13 other live ones, and was the 27th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

8 of the 59 studies testing hydroxyurea in Anemia, Sickle Cell are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About hydroxyurea

Hydroxyurea: first FDA approval 1967 (DROXIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 6 Months to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing hydroxyurea in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

The primary objectives of this prospective study of hydroxyurea for children with sickle cell anemia are 1) Develop and prospectively evaluate a population pharmacokinetic/pharmacodynamics model to predict the maximum tolerated dose (MTD); 2) Identify urine biomarkers of hydroxyurea adherence using a novel metabolomics approach; 3) Identify pharmacogenomics modifiers of hydroxyurea MTD; and 4) Longitudinal monitoring of the effect of hydroxyurea upon organ function and quality of life.

Read the detailed description

There is now ample clinical evidence that hydroxyurea is a safe and effective medication for adults and children with sickle cell anemia (SCA), and most hematologists agree the short-term safety and efficacy of hydroxyurea has been proven. The National Heart, Lung, and Blood Institute have recently released evidence-based guidelines for SCA, recommending that hydroxyurea be offered to all affected children as young as nine months of age, regardless of clinical severity. Despite the overwhelming evidence demonstrating safety and efficacy, hydroxyurea remains underutilized for a variety of reasons. In this prospective study, the investigators will utilize innovative strategies designed to address and overcome some of the barriers that currently limit the use of hydroxyurea for children with SCA. The investigators will utilize novel laboratory techniques and pharmacometric modeling in order to accurately predict the most effective hydroxyurea dose referred to as the maximum tolerated dose. The investigators aim to develop a screening urine test to objectively and accurately determine adherence to hydroxyurea therapy. In addition, the study will document critical laboratory and clinical characteristics of this unique population of patients with SCA who begin hydroxyurea at a young age.

This study will follow two groups of patients. The first group, referred to as the New Cohort, will include mostly young infants who are not receiving hydroxyurea therapy upon entering the study. The starting dose of hydroxyurea for each of the participants in the New Cohort will be individually determined using the novel population PK/PD dose-prediction model. The second group of study participants, referred to as the Old Cohort, will include patients who are already receiving hydroxyurea therapy upon study entry. Both the Old and New Cohort (New Cohort) will be included in the development of a urine biomarker of adherence and will be followed throughout the study to document the effect hydroxyurea has upon organ function and quality of life. It is important to note that this is not a therapeutic drug trial. Prior to enrollment in the study, participants, along with their families and clinical providers, have decided to initiate hydroxyurea therapy for clinical indications. Except for the dose prediction model for the New Cohort, participants will be treated and monitored according to the routine clinical practice guidelines of the Cincinnati Children's Hospital Comprehensive Sickle Cell Center.

03

Conditions studied

  • Anemia, Sickle Cell

Browse trials for

Keywords

  • Hydroxyurea
  • Sickle Cell
  • Pharmacokinetics
  • dynamics
  • genomics
04

Who can participate

Ages eligible
6 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of sickle cell anemia (HbSS or β0-thalassemia)
  2. Age 6 months to 21 years at the time of enrollment
  3. Clinical decision by patient, family, and healthcare provider to initiate hydroxyurea therapy, including patients who are transitioning from chronic transfusions to hydroxyurea therapy

Exclusion criteria

Exclusion Criteria:

1. Family unwillingness to sign or comply with study treatments

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Hydroxyurea

    All enrolled participants will receive hydroxyurea, but upon enrollment, participants will be identified as part of the "New Cohort" or "Old Cohort" "New Cohort" participants include those who are not receiving hydroxyurea therapy upon study entry. "Old Cohort" participants include those who are already receiving hydroxyurea therapy upon study entry. New Cohort participants will have starting dose predicted using PK/PD data and Old Cohort participants will continue dosing per clinical guidelines.

    Drug: Hydroxyurea

Interventions

  • For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.

06

What researchers measure

Primary outcomes

  1. Time to Reach Maximum Tolerated Dose (months)

    Time it takes to reach maximum tolerated dose (MTD) of hydroxyurea quantified in months.

    Time frame: Twelve months

Secondary outcomes

  1. Hydroxyurea adherence

    Hydroxyurea adherence as measured by analysis of urine metabolites

    Time frame: Monthly until MTD then yearly up to ten years

  2. Neurological function

    Neurological function as measured by transcranial Doppler study (yearly), brain MRI (every 5 years beginning at age 5).

    Time frame: Yearly

  3. Non-invasive Transcranial Cerebral Oximetry

    Non-invasive transcranial cerebral oximetry

    Time frame: Monthly until MTD then every six months, up to ten years

  4. Splenic function

    Splenic function as measured by pocked red blood cell counts ("pit counts")

    Time frame: Annually up to ten years

  5. Kidney function

    Kidney function as measured by BUN/creatinine, urinalysis, and cystatin-C

    Time frame: Annually, up to ten years

  6. Cardiac function (assessment and growth)

    Cardiac function as measured by echocardiogram and ECG

    Time frame: Every Five Years, up to 21 years of age

  7. Assessment of Growth

    Assessment of growth as defined by height and weight

    Time frame: Every six months, up to ten years

07

Study locations

1 site
08

References and documents

Publications

  • Power-Hays A, McElhinney KE, Williams TN, Mochamah G, Olupot-Olupot P, Paasi G, Reid ME, Rankine-Mullings AE, Opoka RO, John CC, McGann PT, Quinn CT, Punt NC, Smart LR, Stuber SE, Latham TS, Vinks AA, Ware RE. Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. Blood Adv. 2026 Jan 27;10(2):418-427. doi: 10.1182/bloodadvances.2025017254. PubMed 41026975 ↗
  • Quinn CT, Niss O, Dong M, Pfeiffer A, Korpik J, Reynaud M, Bonar H, Kalfa TA, Smart LR, Malik P, Ware RE, Vinks AA, McGann PT. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. Br J Haematol. 2021 Aug;194(3):617-625. doi: 10.1111/bjh.17663. Epub 2021 Jul 5. PubMed 34227124 ↗
  • Sadaf A, Quinn CT, Korpik JB, Pfeiffer A, Reynaud M, Niss O, Malik P, Ware RE, Kalfa TA, McGann PT. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells Mol Dis. 2021 Sep;90:102576. doi: 10.1016/j.bcmd.2021.102576. Epub 2021 May 11. No abstract available. PubMed 34020272 ↗
  • McGann PT, Niss O, Dong M, Marahatta A, Howard TA, Mizuno T, Lane A, Kalfa TA, Malik P, Quinn CT, Ware RE, Vinks AA. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. Am J Hematol. 2019 Aug;94(8):871-879. doi: 10.1002/ajh.25510. Epub 2019 Jun 12. PubMed 31106898 ↗
  • Dong M, McGann PT, Mizuno T, Ware RE, Vinks AA. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol. 2016 Apr;81(4):742-52. doi: 10.1111/bcp.12851. Epub 2016 Feb 5. PubMed 26615061 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2014 (actual). Primary completion is estimated for Dec 2026, 146 months after the start.

Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 146 months is above that.

Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2014
First posted
Nov 7, 2014
StartActual
Oct 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02286154
Responsible party
Sponsor
First posted
Nov 7, 2014
Start date
Oct 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 17, 2025

Study contacts

Charles Quinn, MD, MS
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxyurea

Start the discussion